Author details

Full Name

Emanuele Palescandolo

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
30559381	Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2019
29765031	Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes.	Nat Commun	2018
25063326	Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.	Journal of the National Cancer Institute	2014
25316818	Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.	Clin Cancer Res	2014
25157968	Prospective enterprise-level molecular genotyping of a cohort of cancer patients.	J Mol Diagn	2014
23334667	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.	Nat Genet	2013
24037752	Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.	Cancer	2013
24066160	Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency.	PLoS One	2013
22067401	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	J Clin Oncol	2012
22727996	BRAF mutations in metanephric adenoma of the kidney.	Eur Urol	2012
22460905	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2012
22723903	High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma.	PLoS One	2012
22870241	High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.	PLoS One	2012
22977135	High throughput mass spectrometry-based mutation profiling of primary uveal melanoma.	Invest Ophthalmol Vis Sci	2012
21931712	High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.	PLoS One	2011
19318631	Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.	J Natl Cancer Inst	2009
18838960	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.	Lab Invest	2008
17690711	deltaN-p73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation.	Cell Death and Differentiation	2007
16331689	Pkn is a novel partner of cyclin T2a in muscle differentiation.	Journal of Cellular Physiology	2006
16638877	Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.	Clinical Cancer Research	2006
15867210	Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress.	Clinical Cancer Research	2005
15880455	Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells.	Journal of Cellular Physiology	2005
12032848	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.	Oncogene	2002
11423907	Interplay between the antimetastatic nm23 and the retinoblastoma-related Rb2/p130 genes in promoting neuronal differentiation of PC12 cells.	Cell Death and Differentiation	2001